Category: Pα+ - Page 3 - Psychedelic Alpha

Read more about the article Pα+ Psychedelic Bulletin #188: Q4’24 Lobbying Update; Virginia Lawmakers Question Purpose, Precedent of Compass Bill; VA Loses Psychedelics Champion; GH Discusses Lack of Placebo Effect

Pα+ Psychedelic Bulletin #188: Q4’24 Lobbying Update; Virginia Lawmakers Question Purpose, Precedent of Compass Bill; VA Loses Psychedelics Champion; GH Discusses Lack of Placebo Effect

Post published:February 14, 2025
Post category:Psychedelic Bulletin Pα+

Read more about the article Ketamine on the Edge: Mindbloom’s At-Home Injections Spark Debate; UK Eyes Tougher Laws; DEA to Regulate Telehealth Prescribing; Spravato Sales Top $1bn

Ketamine on the Edge: Mindbloom’s At-Home Injections Spark Debate; UK Eyes Tougher Laws; DEA to Regulate Telehealth Prescribing; Spravato Sales Top $1bn

Post published:February 10, 2025
Post category:Analysis News Pα+

Read more about the article Pα+ Psychedelic Bulletin #187: NYT Article Reignites MDMA Rejection Blame Game; FDA “Wanted to Approve” MDMA, MindMed Exec Says; GH’s Data and RFK Jr. Confirmation Send Psychedelics Stocks Soaring

Pα+ Psychedelic Bulletin #187: NYT Article Reignites MDMA Rejection Blame Game; FDA “Wanted to Approve” MDMA, MindMed Exec Says; GH’s Data and RFK Jr. Confirmation Send Psychedelics Stocks Soaring

Post published:February 7, 2025
Post category:Psychedelic Bulletin Pα+

Read more about the article GH Research Reports Strong Phase 2b Results for 5-MeO-DMT in Treatment-Resistant Depression

GH Research Reports Strong Phase 2b Results for 5-MeO-DMT in Treatment-Resistant Depression

Post published:February 3, 2025
Post category:Analysis News Pα+

Read more about the article 2025’s Psychedelic Policy Surge: A State-by-State, Bill-by-Bill Analysis

2025’s Psychedelic Policy Surge: A State-by-State, Bill-by-Bill Analysis

Post published:January 31, 2025
Post category:Analysis News Pα+

Read more about the article Psychedelic Drug Development Pipeline Updates (Q1’25)

Psychedelic Drug Development Pipeline Updates (Q1’25)

Post published:January 30, 2025
Post category:2024 Year in Review Analysis News Pα+

Read more about the article Pα+ Psychedelic Bulletin #186: As Trump Takes Office, Impact on Psychedelics Field Remains Unclear; The Jurvetsons Discuss Psychedelics at DLD; GH Shares PoC Data

Pα+ Psychedelic Bulletin #186: As Trump Takes Office, Impact on Psychedelics Field Remains Unclear; The Jurvetsons Discuss Psychedelics at DLD; GH Shares PoC Data

Post published:January 24, 2025
Post category:Psychedelic Bulletin Pα+

Read more about the article mpathic Co-Founder Danielle Schlosser on AI Oversight of Psychedelics Trials

mpathic Co-Founder Danielle Schlosser on AI Oversight of Psychedelics Trials

Post published:January 17, 2025
Post category:Interviews Pα+

Read more about the article Patent Analysis: Lykos Suffers Blow from USPTO As All Patent Claims Stand Finally Rejected

Patent Analysis: Lykos Suffers Blow from USPTO As All Patent Claims Stand Finally Rejected

Post published:January 16, 2025
Post category:Psychedelic Patent Analysis Pα+

Read more about the article Pα+ Psychedelic Bulletin #185: Joe Rogan on Ibogaine; Wisconsin Medicaid to Cover IV Ketamine for Depression; Inside the Plan to Make Lykos MAPS Again

Pα+ Psychedelic Bulletin #185: Joe Rogan on Ibogaine; Wisconsin Medicaid to Cover IV Ketamine for Depression; Inside the Plan to Make Lykos MAPS Again

Post published:January 11, 2025
Post category:Psychedelic Bulletin Pα+

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.